Exelixis | EXEL - Ordinary Share Capital



Exelixis reported $270.13M in Ordinary Share Capital for its fiscal quarter ending in July of 2025.


Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 167.36M 167.35M Jun/2025
Agios Pharmaceuticals USD 58.04M 57.96M Jun/2025
Amgen USD 538M 33.04B Jun/2025
AstraZeneca USD 1.55B 1.16B Jun/2025
Bayer EUR 982.42M 1.53B Jun/2025
BioMarin Pharmaceutical USD 192M 191.81M Jun/2025
Bristol-Myers Squibb USD 2.04B 1.74B Jun/2025
Cytokinetics USD 119.6M 119.48M Jun/2025
Eisai JPY 282.12M 44.7B Jun/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Exelixis USD 270.13M 269.86M Jul/2025
Genmab DKK 10M 56M Mar/2025
Glaxosmithkline GBP 4.15B 2.8B Jun/2025
Incyte USD 194.12M 193.93M Jun/2025
Ionis Pharmaceuticals USD 159.2M 159.04M Jun/2025
MacroGenics USD 63.21M 62.58M Jun/2025
Merck USD 1.79B 0 Mar/2025
Moderna USD 389M 388.96M Jun/2025
Neurocrine Biosciences USD 99M 0 Jun/2025
Novartis USD 793M 0 Dec/2024
Pfizer USD 5.68B 5.2B Jun/2025
Sanofi 1.22B 36.5M Jun/2025
Takeda JPY 1.56B 1.69T Jun/2025
Ultragenyx Pharmaceutical USD 96.35M 2.45M Jun/2025
Xencor USD 71.3M 70.58M Jun/2025